Value, Affordability, and Decision Making
Efficient allocation of healthcare budgets requires a clear understanding of whether interventions deliver good value for money. Resource-allocation decisions should therefore follow structured, transparent, and evidence-based processes that consider value, equity, and affordability.
OHE advances innovative methodologies and drives international, policy-focused research to address these core dimensions . We provide evidence in support of robust, systematic, and comprehensive value assessments within healthcare systems, including Health Technology Assessment (HTA), and across other sectors.
Overall purpose of this research theme
To support systematic, fair, and evidence-based decision-making processes for resource allocation in healthcare.
Policy objectives
- Advance the development of novel value frameworks.
- Inform HTA methods and processes.
- Guide the purpose and role of HTA.
- Strengthen knowledge transfer and guidance for decision-makers.
Around the World in HTAs
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
Saudi Arabia’s healthcare system is undergoing a significant transformation, driven by ambitious structural, regulatory and financial reforms outlined in Vision 2030. These changes are creating a dynamic environment for health technologies and their pathway to market.
Read more
Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés Pichon-Riviere, Federico Augustovski, and Martina Garau take us to Argentina.
Read more
Around the World in HTAs: Kenya – Riding the Waves of Change
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Angela Kairu and Edwine Barasa of the KEMRI Wellcome Trust Research Programme, and Paul Oyalo of OHE, take us to Kenya.
Read more
Around the World in HTAs: Canada – Autonomous yet Collaborative
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Adam Raymakers and Chris Skedgel take us to Canada.
Read moreOur latest content on this theme
Novel devices: optimising drug delivery in multiple myeloma
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
A global landscape analysis of access to tumour-agnostic therapies
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology.
Achieving Accelerated Patient Access to Cancer Care in Europe
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured, multidisciplinary stakeholder engagement process.
The value of cell and gene therapies to the UK economy
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.